Search
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigational[A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis. … [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnIn August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with … Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target
Ginseng
go.drugbank.com/drugs/DB01404ApprovedInvestigationalNutraceuticalGinseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties
Mixtures: ApsDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L41900] It is used as monotherapy or in combination with other drugs, such as corticosteroids. … [L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017.
Folic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approvedThis important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted by anti-metabolite therapies such as [DB00563] as they function as DHFR inhibitors to prevent … When used in high doses such as for cancer therapy, or in low doses such as for Rheumatoid Arthritis or psoriasis, [DB00563] impedes the body's ability to create folic acid.
Mixtures: Daily Energy Brand B-complex, Doctor's Choice Brand for MenProducts: ACIDO FOLICO DOC GENERICIEthylhexyl methoxycrylene
go.drugbank.com/drugs/DB11226ApprovedIt currently enjoys regional approvals in Canada, the EU, and the US [L2847]. … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various lotions, creams, sprays, sticks, and gel formulations [F104].
Riboflavin
go.drugbank.com/drugs/DB00140ApprovedInvestigationalNutraceuticalVet approvedIt occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide.
Mixtures: Daily Energy Brand B-complex, Doctor's Choice Brand for MenEtryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnSimilarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.
Spaglumic acid
go.drugbank.com/drugs/DB08835InvestigationalSpecifically spaglumic acid is approved in Portugal under the brand name Naabak and in Greece under the brand name Naaxia for use in patients with allergic conjunctivitis. … Thus it is used in allergic conditions such as allergic conjunctivitis.